Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer Safety of Avastin in Lung trial (MO19390)

SFX Get it!(opens in a new window)|View at Publisher| Export | Download | More... Journal of Thoracic Oncology Volume 7, Issue 1, January 2012, Pages 203-211 Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: Safety of avastin in lung trial (MO19390) (Article) Laskin, J.a , Crinò, L.b, Felip, E.c, Franke, F.d, Gorbunova, V.e, Groen, H.f, Jiang, G.-L.g, Reck, M.h, Schneider, C.-P.i a Medical Oncology Department, BC Cancer Agency, Vancouver, BC V5Z 4E6, Canada b Department of Oncology, Hospital S. Maria della Misericordia, Perugia, Italy c Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain d Hospital de Caridade, Ijuí, Brazil e Cancer Research Center, Moscow, Russian Federation f Department of Pulmonary Diseases, University Hospital Groningen, Groningen, Netherlands g Fudan University Shanghai Cancer Center, Shanghai, China h Department of Thoracic Oncology, Hospital Grosshandorf, Grosshansdorf, Germany i Department of Oncology, Central Clinic Bad Berka, Bad Berka, Germany View additional affiliations View references (33) Abstract Introduction: Safety of Avastin in Lung (MO19390) was an international, open-label, single-arm study, which assessed the safety and efficacy of first-line bevacizumab (Avastin®) in combination with standard chemotherapy in patients (n = 2212) with advanced or recurrent non-small cell lung cancer (NSCLC). A preplanned subgroup analysis was performed to examine these outcomes in elderly patients older than 65 years. Methods: Eligible patients with nonsquamous NSCLC received up to six cycles of bevacizumab (7.5 or 15 mg/kg) plus any standard of care chemotherapy. Patients who did not experience disease progression after induction therapy continued bevacizumab therapy until disease progression or unacceptable toxicity. The primary end point was safety; secondary end points included time to disease progression (TTP) and overall survival (OS). Results: Data were evaluated for 623 patients older than 65 years (mean age 70.6). The majority were Whites (86.2%) with stage IV disease (79.7%) and had adenocarcinoma (83.5%). The incidence of adverse events (AEs) of special interest was similar for elderly and younger patients (any grade bleeding 38.2% versus 38.3%; any grade hypertension 33.1% versus 30.6%; any grade proteinuria 33.4% versus 29.3%). Most AEs were grade less than or equal to 2. Serious AEs were reported in 45.3 and 34.7% of elderly and younger patients, respectively. Median OS was similar in elderly and younger patients (14.6 months in both age groups), as were TTP (8.2 versus 7.6 months), response rate (49.3% versus 52.4%), and disease control rate (89.3% versus 88.4%). Similar results were seen in a post hoc comparison of the older than 70 years and 70 years or younger subgroups: TTP was 8.6 months versus 7.7 months, respectively; OS was 14.6 months in both subgroups; response rate was 49% and 52%, respectively; incidence of AEs of special interest was comparable. Conclusion: Patients older than 65 years with nonsquamous NSCLC derive a similar clinical benefit from first-line bevacizumab-based therapy as their younger counterparts and do not experience increased toxicity.